SaveHealth reports that insulin therapy is crucial for diabetes management, with various options available, including rapid- and long-acting insulins.

The FDA has expanded the indication for Toujeo (insulin glargine; Sanofi) 300 Units/mL to include treatment of pediatric patients aged ≥6 years with diabetes mellitus. The Food and Drug Administration ...

The FINANCIAL — Sanofi announced on July 3 that the Ministry of Health, Labor and Welfare (MHLW) in Japan granted marketing authorization for insulin glargine [rDNA origin] injection, 300 U/mL, a next ...

* CHMP adopts positive opinion for expanded indication for Toujeo in children and adolescents (aged 6 to 17 years) with diabetes The trial, EDITION JUNIOR, is the first randomized, controlled trial ...

Significant results from an international phase 3 study, EDITION, resulted in the approval of Toujeo in treating patients with type 1 as well as type 2 diabetes. Sanofi announced today that the FDA ...

The FINANCIAL — Sanofi announced on April 28 that the European Commission has granted marketing authorization in Europe for Toujeo (insulin glargine [rDNA origin] injection, 300 U/mL), a ...

Make no mistake, the power of the PBMs is growing and they are not afraid to wield it. The decision by the PBM (pharmacy benefit manager) CVS (CVS) to exclude Sanofi’s (SNY) core insulin products ...

Sanofi (Euronext: SAN; NYSE: SNY) announced today that it received FDA approval for its Toujeo Max SoloStar insulin pen, the highest capacity long-acting insulin pen that will be available on the ...

A century ago, type 1 diabetes was a death sentence. Children diagnosed rarely survived more than a year or two, wasting away as their bodies starved despite food. Then, in 1921, in a modest lab in ...